Tailored Risk Management Per Study and Per Protocol
- The RTSM team begins with a review of a library of 200+ clinical trial risks, including unintentional unblinding, to weigh and mitigate those for each study
- Every data point entered in and provided by RTSM for the study is assessed, identifying whether each could fully or partially unblind alone or in combination
- The RTSM designer understands from the sponsor which roles are permitted to know what data
- The team of SMEs will review protocol, packaging, and study-specific risks on an ongoing basis, reviewing mitigating actions and evaluating any changes.